Clinical Trials
2 trialsNCT05625399 2026-06-03
RELATIVITY-127
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT06101134 2026-04-09
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Bristol-Myers Squibb
Phase 2 Active not recruiting